6MX.F - Eidos Therapeutics, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Annual

Cash Flow

All numbers in thousands
Breakdown
ttm
2019-12-31
2018-12-31
2017-12-31
2016-12-31
Cash flows from operating activities
Net Income
-48,926
-37,835
-40,725
-11,941
-2,542
Depreciation & amortization
89
77
56
4
0
Stock based compensation
6,336
5,373
2,526
1,148
107
Change in working capital
1,825
622
826
1,142
209
Accounts Payable
760
1,195
1,390
472
52
Other working capital
-40,695
-31,875
-33,291
-9,770
-2,059
Other non-cash items
-
39
1,648
-70
161
Net cash provided by operating activites
-40,417
-31,648
-33,141
-9,717
-2,059
Cash flows from investing activities
Investments in property, plant and equipment
-
-227
-150
-53
-
Net cash used for investing activites
-278
-227
-150
-53
0
Cash flows from financing activities
Common stock issued
71,330
47,236
110,970
-
0
Other financing activites
-
-348
-
-
-
Net cash used privided by (used for) financing activities
90,146
65,885
184,941
13,311
3,990
Net change in cash
49,451
34,010
151,650
3,541
1,931
Cash at beginning of period
147,064
157,147
5,497
1,956
25
Cash at end of period
196,515
191,157
157,147
5,497
1,956
Free Cash Flow
Operating Cash Flow
-40,417
-31,648
-33,141
-9,717
-2,059
Capital Expenditure
-
-227
-150
-53
-
Free Cash Flow
-40,695
-31,875
-33,291
-9,770
-2,059